

CHAIR

Bruce R. Korf, MD, PhD

PeerView
Live

1.0 CME/MOC/NCPD/CPE

Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas

Improving Patient Outcomes With an Innovative Therapeutic Approach

Date: Friday, April 1, 2022

Time: 12:00 PM - 1:00 PM CT

Faculty: Bruce R. Korf, MD, PhD

DATE	LOCATION	FACULTY
Friday, April 1, 2022 12:00 PM - 1:00 PM CT	Zoom Please email admin@nfnetwork.org for registration link.	Bruce R. Korf, MD, PhD Associate Dean for Genomic Medicine, UAB School of Medicine Chief Genomics Officer, UAB Medicine Wayne H. And Sara Crews Finley Endowed Chair in Medical Genetics University of Alabama at Birmingham

Activity Description

Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease.

This live activity will provide expert insights into the pathophysiology of NF-1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF-1 will be presented.

Educational Objectives

Upon completion of this CE activity, participants will be able to:

- Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1)
- Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF-1-associated tumors
- Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors)
- Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1-related plexiform neurofibromas and other tumors in pediatric and adult patients
- Incorporate MEK inhibitors into treatment plans for patients with NF-1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and 1.0 Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: To be provided on record of participation.

Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.